Pluripotent Stem Cell-Derived Pancreatic Progenitors and β-Like Cells for Type 1 Diabetes Treatment
Author(s) -
Rangarajan Sambathkumar,
Adriana Migliorini,
M. Cristiostro
Publication year - 2018
Publication title -
physiology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.14
H-Index - 125
eISSN - 1548-9213
pISSN - 1548-9221
DOI - 10.1152/physiol.00026.2018
Subject(s) - induced pluripotent stem cell , progenitor cell , stem cell , cell , cell type , safer , pancreas , biology , in vitro , cell therapy , in vivo , type 2 diabetes , microbiology and biotechnology , bioinformatics , diabetes mellitus , computational biology , embryonic stem cell , computer science , endocrinology , biochemistry , computer security , gene
In this review, we focus on the processes guiding human pancreas development and provide an update on methods to efficiently generate pancreatic progenitors (PPs) and β-like cells in vitro from human pluripotent stem cells (hPSCs). Furthermore, we assess the strengths and weaknesses of using PPs and β-like cell for cell replacement therapy for the treatment of Type 1 diabetes with respect to cell manufacturing, engrafting, functionality, and safety. Finally, we discuss the identification and use of specific cell surface markers to generate safer populations of PPs for clinical translation and to study the development of PPs in vivo and in vitro.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom